Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: Targeting the pathogenic activation of mTORC1 in tumors

Journal of Clinical Oncology

Volumn 28, Issue 5, 2010, Pages 835-840

  Wagner, Andrew J ^a   Malinowska Kolodziej, Izabela ^a   Morgan, Jeffrey A ^a   Qin, Wei ^a   Fletcher, Christopher D M ^a   Vena, Natalie ^a   Ligon, Azra H ^a   Antonescu, Cristina R ^a   Ramaiya, Nikhil H ^a   Demetri, George D ^a   Kwiatkowski, David J ^a   Maki, Robert G ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE MTORC1; RAPAMYCIN; SORAFENIB; SUNITINIB; TUBERIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; MAMMALIAN TARGET OF RAPAMYCIN; MTORC1 PROTEIN, HUMAN; SIGNAL PEPTIDE; TRANSCRIPTION FACTOR; TUBEROUS SCLEROSIS COMPLEX 1 PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER FATIGUE; CANCER GROWTH; CANCER SURGERY; CASE REPORT; CLEAR CELL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG TOLERABILITY; FEMALE; GENE LOSS; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; PERIVASCULAR EPITHELIOID CELL TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA; TREATMENT RESPONSE; TSC 1 TUMOR SUPPRESSOR GENE; TUMOR SUPPRESSOR GENE; CHEMISTRY; CLINICAL TRIAL; DRUG ANTAGONISM; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; RADIOGRAPHY; TIME; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, ORAL; AGED; ANTIBIOTICS, ANTINEOPLASTIC; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; PERIVASCULAR EPITHELIOID CELL NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; SIROLIMUS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS; UNITED STATES;

EID: 77649215630     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.2981     Document Type: Article

References (17)

1. Wagner A: Treatment of advanced soft tissue sarcoma: Conventional agents and promising new drugs. J Natl Compr Canc Netw 5:401-410, 2007
2. Hornick JL, Fletcher CD: PEComa: What do we know so far? Histopathology 48:75-82, 2006
3. Folpe AL, Kwiatkowski DJ: Perivascular epithelioid cell neoplasms: Pathology and pathogenesis. Hum Pathol 10.1016/j.humpath.2009.05.011 [epub ahead of print on July 15, 2009]
4. Folpe AL, Mentzel T, Lehr HA, et al: Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: A clinicopathologic study of 26 cases and review of the literature. Am J Surg Pathol 29:1558-1575, 2005 (Pubitemid 43754477)
5. Bissler JJ, McCormack FX, Young LR, et al: Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358:140-151, 2008
6. Pan CC, Chung MY, Ng KF, et al: Constant allelic alteration on chromosome 16p (TSC2 gene) in perivascular epithelioid cell tumour (PEComa): Genetic evidence for the relationship of PEComa with angiomyolipoma. J Pathol 214:387-393, 2008
7. Kenerson H, Folpe AL, Takayama TK, et al: Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms. Hum Pathol 38:1361-1371, 2007 (Pubitemid 47247479)
8. Kozlowski P, Roberts P, Dabora S, et al: Identification of 54 large deletions/duplications in TSC1 and TSC2 using MLPA, and genotype-phenotype correlations. Hum Genet 121:389-400, 2007 (Pubitemid 46554675)
9. Firestein R, Bass AJ, Kim SY, et al: CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature 455:547-551, 2008
10. Benvenuto G, Li S, Brown SJ, et al: The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. Oncogene 19:6306-6316, 2000 (Pubitemid 32641844)
11. Herry I, Neukirch C, Debray MP, et al: Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complex. Eur J Intern Med 18:76-77, 2007 (Pubitemid 46091655)
12. Taillé C, Debray MP, Crestani B: Sirolimus treatment for pulmonary lymphangioleiomyomatosis. Ann Intern Med 146:687-688, 2007
13. Wienecke R, Fackler I, Linsenmaier U, et al: Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex. Am J Kidney Dis 48:e27-e29, 2006
14. Hofbauer GF, Marcollo-Pini A, Corsenca A, et al: The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. Br J Dermatol 159:473-475, 2008 (Pubitemid 352009863)
15. Chawla SP, Tolcher AW, Staddon AP, et al: Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients with advanced soft tissue or bone sarcomas. J Clin Oncol 24:521s, 2006 (suppl; abstr 9505)
16. Okuno SH, Mahoney MR, Bailey HH, et al: A multicenter phase II consortium study of the mTOR inhibitor CCI-779 in advanced soft tissue sarcomas. J Clin Oncol 24:521s, 2006 (suppl; abstr 9504)
17. Iwenofu OH, Lackman RD, Staddon AP, et al: Phospho-S6 ribosomal protein: A potential new predictive sarcoma marker for targeted mTOR therapy. Mod Pathol 21:231-237, 2008